Preliminary Program

revised 04 Nov 2026



PA Research Foundation

Cancer Council Queensland

Dear Colleagues,
Welcome to the 13th Annual Brisbane Cancer Conference being held over 2 days on Thursday and Friday the 26-27th November 2026 at the Brisbane Convention and Exhibition Centre and supported by the Princess Alexandra Research Foundation (PARF) and Cancer Council Queensland (CCQ). This meeting is an opportunity to draw together cancer researchers in Brisbane, Queensland, Northern New South Wales and Darwin to advance collaborative efforts in cancer research.

The meeting comprises plenary lectures and workshops on recent scientific, technological, nursing, advocacy and medical developments in the diagnosis, treatment and research of malignant disease.

On Thursday 26th November, the meeting starts at 8.00am with Breast, Lung and Prostate Cancer, Survivorship and Immuno-oncology symposia running from 8 – 12 midday in the morning.

The symposia will be followed by plenary lectures and a 'Cutting-Edge Research' symposium focused this year on epidemiology. Subsequently there will be workshops from 4.30–6.00pm. The symposium Gala dinner will be held on Thursday evening from 7.00pm offering the opportunity to socialise and network with colleagues and patient advocates/consumers.

The all-day session on Friday 27th November will include plenary lectures followed by workshops in the morning and afternoon. A key session will be plenary lectures by oncology researchers starting at 12.30pm that have contributed to global advances in our understanding of the epidemiology, molecular biology and treatment of malignant disease. Over 1600 delegates registered for and attended the event last year demonstrating the value of a truly multi-disciplinary annual Queensland Translational Cancer Research focused conference in Brisbane.

This conference is made possible not only through the support of PARF and CCQ, but also our many sponsors from our academic centres, in particular QIMR Berghofer, industry, philanthropy and the time and effort of the chairs who put the symposia and workshops together. I would also like to extend my special thanks to the QUT CARP and Centre for Genomics and Personalised Health, the UQ Queensland Spatial Biology Centre and Wesley Research Institute teams for their generous voluntary clerical support that they provided each year throughout the meeting.

Best wishes for what should be an enjoyable and fulfilling two days.
Yours sincerely,



Professor Ken O'Byrne
Consultant Medical Oncologist and Clinical Scientist
Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology

Day 1 - Thursday 26th November 2026
Registration opens at 7am
Coffee cart sponsored by the Translational Research Institute Australia
Symposia 8.00 - 12.00 midday (with sponsored Tea Breaks from 10.00-10.30)

Prostate Cancer **P6**
Chairs: Luke Nicholls, Robert Mason, Colleen Nelson
08.00 - Identifying area profiles underpinning observed spatial inequities in prostate cancer incidence and survival - Kou Kou
08.20 - Rad Onc Trials updates - Marcus Hu
08.40 - Med Onc Trials updates - Niara Oliveria
09.00 - Radiation Safety - Brad Franks
09.20 - Theranostics inc. TheraPb - Roslyn Francis
09.40 - Navigating the ARPI tsunami - Helen Anderson
10.00 – Morning tea
10.30 - Immunogenicity of prostate cancer - Prof Jason Lee
11.00 – TBC – Jyotsna Batra
11.30 – Novel approaches to systemic therapy: trials ongoing in Queensland and Australia – Robert Mason

Immuno-Oncology Plaza Level **P7 & P8**
Chairs: Antiopi Varelias, Rajiv Khanna
08.00 - Personalized vaccines for childhood brain cancer - Brandon Wainright
08.20 - Immune therapy in Head and Neck cancer – Brett Hughes (TBC)
08.40 - Expansion of immune-oncology therapeutics in non-melanomatous skin cancer – Rahul Ladwa
09.00 - Immuno-oncology in gastro-intestinal tract tumours - Michael Fernando
09.20 - Tumour cell-intrinsic determinants of immunotherapy response - Kum Kum Khanna
09.40 - Liver-specific barriers to effective cancer immunotherapy - Jet Hou
10.00 - Morning tea *supported by Astrazeneca*
10.30 - IL-6 receptor inhibition promotes expansion of cytolytic CD4+ T cells after cellular immunotherapy - Antiopi Varelias
10.45 - Complement Receptors and the Tumour Microenvironment - Barbara Rolfe
11.00 - NDL2, a first-in-class PD-L1 protein degrader that represents a new frontier in cancer immunotherapy - Sudha Rao
11.15 - Novel cell-based approaches to immune therapy – Andrea Henden
11.45 - Management of Cell-based Therapy Toxicities in Oncology - TBD

Breast Cancer **P9**
Theme: Clinical and Translational Breast Cancer Research: Focus on Lobular Breast Cancer
Chairs: **Pete Simpson, Jasotha Sanmugarajah, Rik Thompson, Kim-Lin Chiew, Leonie Young**
08.00 - Introduction to lobular breast cancer – Pete Simpson
08.05 - Hiding in plain sight: the lobular conundrum - Karin Steinke
08.25 - Surgical management of ILC - Tony Mallet
08.55 - Histopathological diagnosis of invasive lobular carcinoma - Anna Sokolova
09.15 - Optimising Management of Early HR+ Breast Cancer - Kathy You
09.35 - Precision oncology in Lobular Breast Cancer: What is Ready, What is Promising and What Has Failed Tivya Kulasegaran
10.00 - Morning tea *supported by Astrazeneca*
10.30 - Overview and oversights of ILC in radiation oncology - Nicola Lowrey
11.00 - Emerging opportunities in molecular imaging and therapy for lobular breast cancer in 2026 and beyond – Roslyn Francis
11.20 - Case-based MDT discussions & molecular insights - Owen Ung, Amy McCart Reed/Pete Simpson

Survivorship: **P10 & P11**
Session 1 Theme: From Ideation to Implementation: How have we progressed from ideation to implementation of best-practice cancer survivorship care in Queensland?-
08.00 - Welcome and Update from the Queensland Collaborative for Cancer Survivorship (QCCS) - Kim Alexander

08.12 - Survivorship Care in Australia and Beyond – Carla Tham
08.24 - A cancer survivorship service model in private practice – Breast Cancer Wellness Clinics, GenesisCare – Natasha Keir
08.36 - A cancer survivorship service model in a public health organisation – Far North Queensland First Nations Cancer Wellness Service - Jay Haldane
08.48 - A randomised controlled trial of the Pancreatic cancer Relatives Counselling and Education 09.15 - Support Service (PRoCESS): effects on carer and patient outcomes - Vanessa Beesley
09.00 - Optimising access to cancer care for rural and remote communities: A narrative review and baseline audit of Cancer Council's 13 11 20 phone line to inform the design and delivery of Australia's new Cancer Navigation Service - Elizabeth Johnston
09.12 - Exploring patterns of outpatient appointment non-attendance to inform equitable cancer survivorship: findings from a mixed-methods study – Brighid Scanlon
09.24 - The Financial Impact of Metastatic Breast Cancer: Insights from a Qualitative Study in the Australian Context - Ashleigh Sharman

09.36 - What wellness means during cancer: implications for Survivorship - findings from qualitative interviews in the oncology waiting room – Morgan Farley
09.48 - Real-World Experiences of Electronic Patient-Reported Outcome Measures in Cancer Care: A Qualitative Exploration of Patient, Carer and Health Professional Perspectives - Rebecca Packer
10.00 - Morning tea
Session 2 Theme: Barriers and Facilitators in Implementing Cancer Survivorship Care Models for Queenslanders
10.20 Debate: *"The environment exists in Queensland for implementation of best-practice cancer survivorship care."*
Chair - Holly McMillan – Introduction
10.24 - Speaker #1 – Affirmative - Sandra Gleaves (confirmed)
10.30 - Speaker #1 – Negative - Sandi Hayes (confirmed)
10.36 - Speaker #2 – Affirmative - Morgan Farley (confirmed)
10.42 - Speaker #2 – Negative - Anton Cavalli (confirmed)
10.48 – *Audience Q&A (via Slido)* - Audience chairs – Leilani Way/Xiomara Skrabal Ross
10.58 – Final remarks – Affirmative – Affirmative team
11.00 – Final remarks – Negative – Negative team
11.02 – Audience vote (via Slido) – Leilani Way/Xiomara Skrabal Ross
11.05 – Debate results and close session – Holly McMilllan
Session 3 Theme: Overcoming the current barriers and facilitators to implementation of best-practice cancer survivorship care in Queensland
Chair: Harry Gaspar
Panellists: Haakan Jakobsson, Jay Haldane, Madison Purkis, Melissa Eastgate
11.10 - Introduction of topic and panellists – Harry Gaspar
11.15 – Panel Discussion
11.35 – Audience questions (vis Slido) - Leilani Way / Xiomara Skrabal Ross
11.45 – Session close – Harry Gaspar/Kim Alexander

Lung Cancer symposium
What's to be done with the nodule **P5**
Chairs: Henry Marshall, Mark Adams, Kelly McGrath
08.00 - Overview of screening in Australia: A Queensland Focus on The Lung Cancer Screening Program in Australia – Where are we now? Henry Marshall
08.30 - Management of clinically detected and treated stage I tumours
08.45 - Radiology - Catherine Jones
09.00 - Diagnostics - David Fielding
09.15 - Cryosurgery - Alan Carew
09.30 - Radiotherapy - TBC
09.45 - Robotic surgery - Paul Peters
10.00am – *Morning tea supported by AstraZeneca*
10.30 - Adjuvant therapy for stage I disease: patient selection and clinical trials options – Cienne Morton

10.55 - Epidemiology - the established and possible - obesity, exercise (lack of), pollution, diet, Insecticides/pesticides – Lidia Morawska
11.25 - Inflammation and glycolysis, novel targets for chemoprevention? - Kenneth O'Byrne
11.45 - Panel discussion

12.00 Break

Cutting Edge Research: Epidemiology 12.15 **Plaza Auditorium**
Co-chairs: David Whiteman, Peter Baade
12.15 – How can we actually prevent more cancer? What are the next-generation prevention priorities for Australia? –Susan Jordan
12.40 - Roadmap for a National Targeted Melanoma Screening Program: current status and progress – outcomes and survival - Louisa Collins
13.05 - What determines whether people survive cancer? From evidence to better cancer care and outcomes - Penny Webb

Lunch 13.30 – 14.00

Plenary Lectures 14.00 -16.00 **Plaza Auditorium**
Chairs: Nathalie Trott, Doreen Tapsall
14.00 - A cancer survivorship service model in a non-government organisation – Prostate Cancer Foundation of Australia - Jeff Dunn
14.20 - Voluntary Assisted Death (VAD): International, National and Local - Pretoria Bilinski
14.40 - Multi-omics reveals key molecular and cellular features of advanced small cell lung cancer associated with distinct therapeutic opportunities – Katia Nones
15.00 - *Big Data - Danico*
15.30 - Tailoring hormonal strategies with radiotherapy in non-metastatic prostate cancer – David Pryor

Refreshments: 16.00-16.30

Parallel Workshops: 16.30-18.00
Survivorship **P6 & 7**
Session Title: The Queensland Collaborative for Cancer Survivorship: Survivorship Research Outcomes in Queensland
Chairs: Laurelie Wishart
16.30 - The First Year After Ovarian Cancer Diagnosis: A Systematic Review of Survivorship Outcomes - Sara Ali
16.43 - Community members as research partners: A scoping review of consumer training programs in cancer research - Elizabeth Johnston
16.56 - The effect of dietary interventions on cancer survival: A living systematic review and meta-analysis of randomised controlled trials - Brooke Baker
17.09 - Post-treatment nutrition interventions for childhood cancer survivors - Susannah Ayre Facilitators,
17.22 – Motivators and Barriers for Physical Activity in Adolescents and Young Adults Cancer Survivors: A Multi-Stakeholder Participatory Study - Xiomara Skrabal Ross
17.35 - A Moving Target: approaches to help be more precise with exercise prescription to enhance adherence in cancer - Brent Cunningham
17.46 - Does exercise improve survival after a cancer diagnosis? A living systematic review and meta-analysis of randomised controlled trials - Rosa Spence

Non-prostate Genito-urinary malignancies **P8**
Chairs: Jeff Goh, Niara Oliviera
- Overview of clinical trials in Queensland
- Recent advances in MIBC
- Novel radiotherapy approaches in RCC

Multiomics **P9**
Chair: Ciara Lawler, Arutha Kulasinghe

16.30 - Spatial multi-omics reveals neuronal differentiation and metabolic adaptation to CDK4/6 inhibition in medulloblastoma - Yibi Chen
16.48 - On-Slide Construction array (OSCA): A Low-cost High throughput platform for Spatial Multiomics Ash Kaur
17.06 - Spatial and temporal dynamics of immunotherapy response in head and neck cancer - Aaron Kilgallon
17. 24 - Development, validation, and application of multi-metabolite scores in etiologic studies of cancer risk Erikka Loftfield
17. 42 - The robustness and effectiveness of nearest neighbour distributions as a measure of cell type co-localisation in spatial omic datasets – Cooper Janke

Head and neck cancer **P10**
Chairs: Margaret McGrath, Catherine Barnett, Rahul Ladwa

Clinical trials **P11**
Chairs: Dan McKavanagh, Marissa Ryan
16.30 - Implementation of the Clinical Trials Registrar Training Program - Helen Phillips & Liam King
16.42 - Catalogue Of Materials used in the Preparation and Administration of cancer clinical Trial Investigational products to improve the efficiency of suitaBiLity assessments of Equipment (COMPATIBLE) - Sarah Mott
16.54 - Optimising clinical trial quality and efficiency: Audit practices and learnings and the role of our centralised delivery team versus onsite teams - Priya Iyer
17.06 - Advancing cancer clinical trials service: Expanded roles for clinical trials pharmacy clinical assistants. - Celine Sunga
17.18 - Dietary biomarker development in randomized controlled feeding trials: Advancing research on moderate daily alcohol drinking, ultra-processed food intake, and cancer risk - Erikka Loftfield
17.36 - Does timing and concomitant medicines matter? A retrospective review of immune checkpoint inhibitor efficacy with respect to time-of-day administration and concomitant medicines - Maia Ismail & Madelaine Washbourne
17.48 - Expanding Clinical Trial Access in Regional Australia: Challenges, Successes and Lessons Learned from Darling Downs Health - Abil Saj

Gala Dinner, 7.15pm 'til late **Boulevard Room**

Day 2 - Friday 27th November 2026
Brisbane Convention and Exhibition Centre
Registration Opens at 7.00am

Plenary Lectures - 8.00 – 10.00 **Plaza Auditorium**
Chairs:
8.00 - The Remarkable Advances in Small Cell Lung Cancer: Is cure on the horizon? - Wen Xu
8.25 - Beyond the BMA and Advances in AYA Cancer Care - Rick Walker & Imogen Andrews
8.50 - Same cancer, different neighbourhood — how tissue shapes the immune response in lymphomas of the brain and testis – Colm Keane
9.15 - Cell based therapies: a new paradigm of care in solid tumours – Aya El-Helali
9.45 - Panel discussion: Chairs and Speakers

Parallel Workshops 10.15 – 12.00

Youth Cancer workshop **P5**
Strengthening AYA Futures: A Statewide Model of Wrap around Cancer Care
Queensland Youth Cancer Service (QYCS)
Chairs: Rick Walker, Katie Lindeberg
10.15 - QYCS: A Statewide Model of Youth Cancer Care - Katie Lindeberg
10.31 - A Tale of Two Cities: A Case Study in Shared Care - Rick Walker & Corinne Ryan
10.57 - Cancer Doesn't Pause Growing Up: Understanding Adolescents and Young Adults (AYA) – Kylie Wheeler

11.13 - Preserving Futures: Fertility Preservation Pathways in AYA Cancer Care - James Bray
11.29 - Treatment Ends, Challenges Remain: Survivorship Care Matters - Sandra Gleaves
11.45 – Discussion: Katie Lindeberg & Dr Rick Walker

Pharmacy Research & Innovation **P6**
Chairs: Dan McKavanagh, Marissa Ryan
10.15 - Uncommon adverse events and complex interactions with targeted anticancer treatments - Gail Rowan
10.32 - Managing cancer in the transplant patient population: pharmacist impact and collaboration - Tracey Tse
10.49 - Pilot Study Evaluating Ginger and Vitamin B6 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Moderate to High Emetogenic Risk Regimens in an Oncology Day Unit - Guru Sule
11.06 - Adding a digital tool to the clinical trials toolbox: Evaluation of the usability, efficiency, and effectiveness of an Investigational Drug System for drug accountability management - Mahfuzul Islam
11:23 - A patient with Triple M: Exploring Rare Immunotherapy Indications and Toxicities - Kris Johnstone
11:40- Timing is everything: Carboplatin-gemcitabine dosing in a patient with renal impairment planned for dialysis - Stacey Letton
11:57 - Concluding remarks

Brain tumours **P7**
Chairs: Mark Pinkham, Kate Cuff, Bryan Day
10.15 - Update on current trials in Queensland for adult glioma – Cassie Turner
10.32 - Phase 2 Trial on IMMUNE-12 (sea cucumber mix) for Glioblastoma Multiforme (GBM) - Janet Scloss
10.49 - Patterns of care for low grade glioma in Queensland - Jon Cher
11.06 - Feasibility, acceptability and preliminary effects of a nurse-led supportive intervention for carers of people with high-grade glioma - Diana Jones
11.23 - Targeting the cell surface proteome of dormant glioma cells - Lachlan Harris
11.40 - Spatial multi-omics reveals neuronal differentiation and metabolic adaptation to CDK4/6 inhibition in medulloblastoma - Yibi Chen

3-D Cancer models **P8**
Chairs: Lisa Philp, Robert Ju, Lauren Aoude. Nikolas Haass
10:15 - Opening remarks
10.25 - 3D Models for Mechanobiology – Dr Meg McFetridge
10.40 - 3D Matrix Type Drives Pre-Clinical Patient-Derived Osteosarcoma Response to Chemotherapy In Vitro - Luke Hipwood
10.55 - Beyond the Surface: Spatially-Resolved Phenotypic Heterogeneity Challenges TFEB's Role in Autophagy - Gisella Edny
11.10 - Bringing the Tumour Microenvironment Back: A 3D Model of Pancreatic Cancer - Emilie Jaune
11.25 - Discovering Novel Immunotherapeutic Options for Colorectal Cancer - Simon Tria
11.40 - Uncovering Dynamic Changes in Tumour-Associated Vasculature Using a Zebrafish Xenograft Model - Elysse Morris
11.55 - Closing remarks and discussion by Symposium Chairs

Gynae-oncology **P9**
Chairs: Carlos Salomon, Kathryn Middleton, John Hooper
10.15 - Antibody drug conjugates in ovarian cancer - Jeff Goh
10.28 - Exploring equity in ovarian cancer treatment in Australia: a population-based study Kate Gersekowski
10.41 - Closing the gap in lymphoedema prevention after gynaecological cancer: from systematic review to clinical trial - Melanie Plinsinga
10.54 - Histone lactylation in ovarian cancer clear-cell carcinoma - Emma Bolderson
11.07 - Risk stratification for endometrial cancer - Tracy O'Mara
11.20 - Using targeted therapy to promote an anti-tumour immune response in high-grade serous ovarian cancer - Jenny Zeng
11.33 - Extracellular vesicle lipid signatures for ovarian cancer diagnosis - Shikha Rani
11.46 - Dissecting intrauterine hormonal therapy resistance using single-cell multi-omics in complex atypical hyperplasia (CAH) and low-grade early-stage endometrial cancer - Asmerom Sengal

Thoracic Malignancies **P10**

Chairs: Tim Edwards, Zulfiqar Otty, Rebecca Kimberley

- What's happening in Lung Cancer: a 20-minute helicopter view - Gary Ng
- Rapid access clinic - Ahbi Joshi
- Liquid biopsy to support tissue diagnosis – David Fielding
- TILs in NSCLC tumours - Aya El-Helali

Immuno-oncology **P11**

Chairs: Rajiv Khanna, Antiopi Varelias

10.15 - Pre-clinical development of Q-2361 to treat tacrolimus-induced keratinocyte transformation - James Wells

10.35 - Developing New Immunotherapy Approaches for Colorectal Cancer - Greg Kelly

10.55 - Cancer metabolism - Nils Halberg

11.15 - Title to be confirmed - Victoria Ling

Lunch 12.00-12.30

Plenary Lectures 12.30-14.00 **Plaza Auditorium**

Chairs: Natalie Trotter

12.30 - ARC Portal - Clare Scott

12.55 - Advances in breast cancer: Novel agents and Prognostic factors - Sherene Loi

13.20 - Inflammageing and cancer: towards cancer prevention - Charlie Swanton

13.45 - Panel Discussion: Chairs and Speakers

Refreshments 14.00

Parallel Workshops: 14.30 – 16.00

Haematology **P6**

Chairs: Melinda Burgess, Rakin Chowdhury

14.30 - Spatial profiling to understand disease progression in MPN - Jasmin Straube

14.45 - Mechanisms of treatment resistance in AML - Paniz Tavakoli

15.00 - Novel immunotherapy combinations in EBV Driven Lymphoma - Joshua Tobin

15.15 - Distinct immune checkpoint landscapes in PCNSL and SCNSL revealed by single-nucleus profiling - Zachary Hawula

Theranostics **P7**

Chairs: Kristofer Thurecht, Roslyn Francis

14.30 - 10D7 from the perspective of a clinician scientist - Tahleesa Cuda

14.45 - Achieving Theranostics through Molecular Design - James Wood

15.00 - Update on trials and Brisbane research pipeline with Clarity Pharmaceuticals - Ellen Van Dam

15.15n- Pb-212 Targeted Alpha Therapy: State of Play and Future Direction - Simon Puttick

15.30 - Molecular Imaging and Nuclear Oncology Asia Pacific: Theranostics in the private sector - Nat Lenzo

15.45 - Alpha emitting therapeutic isotopes. - Matthew Griffiths

Palliative Care **P8**

Chairs: Ben Gunawan

14.30 - Improving Community-Based Anticipatory Prescribing at End-of-Life - Embedding the National Core Community Palliative Medicines List - Arvind Gunasekaran

14.47 - Does Palliative Care involvement influence the administration of systemic oncological treatments in the last month of a person's life? - Dhamayanthi Surendra

15.04 - Reconceptualising Wellbeing in Palliative Care - Claire Stokes

15.21 - Diagnosis-associated Differences in Continuous Subcutaneous Infusion Use and End-of-Life Decision Making: Malignant versus Non-malignant Disease - Vivek Narotam

15.38 – TBA - Anthony Herbet

GI malignancies **P9**
Chairs: Haakan Jacobsson, Vicki Whitehall, Mark Bettington
14.30 – Optimising access to clinical trials in Queensland – Haakan Jacobsson

Melanoma and skin cancer **P10**
Chairs: Marcin Dzeinis, Glen Boyle, Nikolas Haass
14.30 – Opening remarks by Symposium Chairs
14.36 - Fields of oncogene-mutant melanocytes are present in “normal” skin and are enriched near prior melanoma sites – Katie Lee
14.50 - Using spatial transcriptomics to illuminate the impact of low-dose UV on the skin – Huanwei Wang
15.04 - Capacity, context and consequence: the role of autophagy in driving phenotypic heterogeneity in MITF rheostat melanoma spheroids - Gisella Edny
15.18 - Killing Cancer in S-Phase: Exploiting a Window of Replication Vulnerability - Ritu Bhatt
15.32 - Beyond Naevus Counts: Mapping Spatial Patterns of Naevi to Advance Melanoma Risk Assessment - Dilki Jayasinghe
15.46 - Curing melanoma: the amazing cancer vaccine story – Marcin Dzienis
15.55 - Closing remarks and discussion by workshop chairs Haass

Breast cancer **P11**
Theme: New Frontiers in Breast Cancer Research
Chairs: Maina Bitar, Vaibhavi Joshi
14.30 - Mapping E/M-hybrid Cell States in Triple-Negative Breast Cancer - Charles Bidgood
14.48 - A multi-omic approach to predict treatment outcomes and therapy resistance in patients with BRCA1-associated breast and ovarian cancers - Binny Jaradi
15.07 - Implementing risk-stratified breast cancer screening in Australia - Jenny Berkman
15.25 - Mapping the Molecular Events in Young Breast Cancer: A Spatial and Whole-Exome Approach - Vaibhavi Joshi
15.45 - From Genetic Risk to Immune Evasion: Uncovering Tumour-Intrinsic Regulators of Natural Killer Cell Cytotoxicity - Roy Luo

Refreshments: 16.00

Plenary session 16.15 – 17.15 Plaza Auditorium
AI in Cancer Care
Chair and program still being developed

- Imaging - Catherine Jones
- cTILS - TBC
- Pathology attention-based multi-instance learning predicts single-cell gene expression from histopathology - Xiao Tan & Andrew Su
- Clinical patient management - iScribe

Wine and cheese 17.15 - 18.00 et fini! 😊

THE BRISBANE CANCER CONFERENCE WOULD NOT BE POSSIBLE WITHOUT THE AMAZING AND GENEROUS SUPPORT OF OUR 2026 CONFERENCE SPONSORS!

Conference Sponsors

Silver Sponsors

AdvanCell
astellas
AstraZeneca
Bristol Myers Squibb
Cancer Council Queensland
Lilly Oncology
Johnson&Johnson
MSD
QIMR Berghofer
Turner Freeman Lawyers

Bronze Sponsors

AMGEN
Bayer
Boehringer Ingelheim
IOVANCE Biotherapeutics
IPSEN
MEDISON
MERCK
NOVARTIS
Pfizer
Roche
Slater Gordon Lawyers
SUN PHARMA
Takeda
Tasman Health Care

Other Sponsors

Actithera
agrf
Akura
arrotex Pharmaceuticals
RACURA Oncology
TRIO Translational Research Institute Australia